CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 79 enrolled
Drug / intervention
Letrozole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02137538
NCT02137538Phase 4Completed

Randomization to Letrozole vs. Anastrozole in Short Pubertal Males

Stanford University·interventional·Posted May 14, 2014·Updated Jul 15, 2021

In Brief

A Phase 4 clinical trial evaluating Letrozole and Anastrozole for Short Stature. Completed, enrolled 79 participants across 1 site.

Detailed Summary

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShort Stature
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 14, 2014
Enrollment StartNov 18, 2009
Primary CompletionJun 5, 2018
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 12.1 years ago

Interventions

Letrozoledrug

Anastrozoledrug